Drug intelligence / Profile preview

YH005

Development stage: Unknown
Lead developer: RemeGen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

YH005 is a recombinant humanized monoclonal antibody targeting **Claudin 18.2 (CLDN18.2)**, a tight junction protein overexpressed in various gastric and other solid tumors. It serves as the antibody component in the antibody-drug conjugate (ADC) **RC118 (YH005-ADC)**, which has advanced to **Phase 2 clinical trials** for oncology indications. Developed initially by **Biocytogen Pharmaceuticals**, it was out-licensed to **RemeGen** for ADC development following successful preclinical studies using Claudin 18.2 knock-out mice.

Other names: YH-005YH005YH 005

Targets

Claudin 18.2

Beyond the preview

Go deeper on YH005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YH005.

Explore the full profile